Innovation

FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy

The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.

Rules of import and export of biomaterials produced during clinical trials of drugs become effective in Russia

Rules of import and export of biomaterials produced during clinical trials of drugs become effective in Russia from September 1 and will expire on...
spot_imgspot_img

Sanofi-GSK’s Covid vaccine, effective against omicron, could hit the market this year

Sanofi and GSK today announce positive data from their vaccine trial which evaluated an adjuvanted bivalent D614 and Beta...

OSE Immunotherapeutics collaborates with Microsoft to further develop its digital infrastructures

OSE Immunotherapeutics SA today announces that the Company is one of the first biotech startup companies selected by Microsoft...

Rune Labs gets FDA approval to use Apple Watch to track Parkinson’s disease symptoms

San Francisco-based startup Rune Labs on Monday said it received clearance from the U.S. Food and Drug Administration to...

FDA approves Lilly and Incyte’s Olumiant® for alopecia areata

Eli Lilly and Company and Incyte announced  that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib),...

GSK comes close to creating a hard-to-reach RSV vaccine

GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim...

Code Biotherapeutics raises $75 Million to advance programs to treat and cure rare and prevalent genetic diseases

Code Biotherapeutics, Inc., (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized...